⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18082679 | 1.00 | — | — | |
| SCHEMBL19814903 | 1.00 | — | — | |
| SCHEMBL12631990 | 0.91 | GABRR1 (0.35) | — | |
| SCHEMBL3271679 | 0.91 | GABRR1 (0.35) | — | |
| SCHEMBL10138774 | 0.91 | LTA4H (0.41) | — | |
| SCHEMBL17276053 | 0.91 | LTA4H (0.44) | — | |
| SCHEMBL13285738 | 0.91 | LTA4H (0.44) | — | |
| SCHEMBL13005942 | 0.91 | LTA4H (0.41) | — | |
| SCHEMBL19815021 | 0.91 | LTA4H (0.41) | — | |
| SCHEMBL18050391 | 0.91 | LTA4H (0.44) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12466805-B2 | Pharmaceutical compounds | ALMAC DISCOVERY LIMITED (GB) | 2025-11-11 | — | — | US | disclosed |
| EP-4463451-A1 | ANTIDIABETIC COMPOUNDS AND COMPOSITIONS | Rezubio Pharmaceuticals Co., Ltd (CN) | 2024-11-20 | — | — | EP | disclosed |
| CN-116514771-A | Carboxylic acid compound, preparation method thereof and application thereof in medicine | 江苏恒瑞医药股份有限公司 | 2023-08-01 | — | — | CN | disclosed |
| CN-116496258-A | Carboxylic acid compound, preparation method thereof and application thereof in medicine | 江苏恒瑞医药股份有限公司 | 2023-07-28 | — | — | CN | disclosed |
| CN-116472273-A | Antidiabetic compounds and compositions | 宁康瑞珠生物制药(珠海)有限公司 | 2023-07-21 | — | — | CN | disclosed |
| WO-2023134712-A1 | ANTIDIABETIC COMPOUNDS AND COMPOSITIONS | REZUBIO PHARMACEUTICALS CO., LTD (CN) | 2023-07-20 | — | — | WO | disclosed |
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| US-11427552-B2 | Heterocyclic compounds useful in the treatment of disease | EPIGEN BIOSCIENCES, INC. (US) | 2022-08-30 | — | — | US | disclosed |
| CN-109790146-B | Pharmaceutical compounds | 阿尔麦克探索有限公司 | 2022-08-23 | — | — | CN | disclosed |
| EP-3490982-B1 | PHARMACEUTICAL COMPOUNDS | ALMAC DISCOVERY LTD (GB) | 2022-04-20 | — | — | EP | disclosed |
| US-20140357611-A1 | COMPOUNDS AND METHODS OF TREATING OCULAR DISORDERS | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR NIH | 2014-12-04 | — | — | US | disclosed |
| WO-2014130608-A1 | ANTIDIABETIC BICYCLIC COMPOUNDS | MERCK SHARP & DOHME CORP. (US) | 2014-08-28 | — | — | WO | disclosed |
| US-20140235604-A1 | COMPOUNDS AND METHODS OF TREATING OCULAR DISORDERS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2014-08-21 | — | — | US | disclosed |
| US-8722669-B2 | Compounds and methods of treating ocular disorders | CASE WESTERN RESERVE UNIVERSITY (US) | 2014-05-13 | — | — | US | disclosed |
| EP-2697191-A1 | BRANCHED 3-PHENYLPROPIONIC ACID DERIVATIVES AND THE USE THEREOF | Bayer Intellectual Property GmbH (DE) | 2014-02-19 | — | — | EP | disclosed |
| US-20130012493-A1 | NOVEL SPIRO IMIDAZOLONE DERIVATIVES AS GLUCAGON RECEPTOR ANTAGONISTS, COMPOSITIONS, AND METHODS FOR THEIR USE | MERCK SHARP & DOHME CORP. | 2013-01-10 | — | — | US | disclosed |
| US-20120295895-A1 | COMPOUNDS AND METHODS OF TREATING OCULAR DISORDERS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2012-11-22 | — | — | US | disclosed |
| WO-2012139888-A1 | BRANCHED 3-PHENYLPROPIONIC ACID DERIVATIVES AND THE USE THEREOF | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2012-10-18 | — | — | WO | disclosed |
| US-RE43298-E1 | Peptides as NS3-serine protease inhibitors of hepatitis C virus | SCHERING CORPORATION (US) | 2012-04-03 | — | — | US | disclosed |
| US-20110117057-A1 | NOVEL PEPTIDES AS NS3-SERINE PROTEASE INHIBITORS OF HEPATITIS C VIRUS | SCHERING CORPORATION (US) | 2011-05-19 | — | — | US | disclosed |